Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE American: ELMD) is a medical device company that develops, manufactures, and sells airway clearance therapy products, including the SmartVest® Airway Clearance System, for patients with compromised pulmonary function. Company news often highlights its role as a leader in airway clearance technologies and its focus on High Frequency Chest Wall Oscillation (HFCWO) therapy, particularly in the homecare setting.
Newsflow for Electromed frequently centers on financial results, such as quarterly and annual earnings releases that detail net revenues, operating income, net income, and segment performance in direct homecare and non-homecare markets. These announcements often discuss trends in referrals and approvals, sales force expansion, and gross margin dynamics, as well as commentary from management on operational execution and efficiency initiatives.
Investors can also expect corporate and capital markets updates, including announcements about share repurchase authorizations approved by the board of directors and index-related milestones, such as Electromed’s addition to the Russell 2000® and Russell 3000® indexes. The company issues press releases when it schedules earnings conference calls and webcasts, providing dial-in details and replay information.
Another recurring category of news involves investor conference participation. Electromed regularly announces its presence at events hosted by organizations such as Noble Capital Markets, LD Micro, Canaccord Genuity, and Investor Summit, where management presents the company’s airway clearance business and growth strategy to institutional and other investors.
For readers tracking ELMD, this news page provides a centralized view of Electromed’s earnings announcements, capital allocation decisions, index inclusions, and investor outreach activities, offering context on how the company is executing its strategy in the airway clearance therapy market.
Electromed, Inc. (NYSE American: ELMD) released a report detailing findings from a third-party clinical study presented at the American Thoracic Society International Conference in San Francisco. The study demonstrated that patients using high frequency chest wall oscillation (HFCWO) therapy showed improved health outcomes and a reduction in healthcare resource utilization (HCRU), including lower medication usage. The analysis focused on non-cystic fibrosis bronchiectasis patients, emphasizing HFCWO's effectiveness in enhancing patient care and reducing hospitalizations.
Electromed, Inc. (NYSE American: ELMD) reported a 15.4% revenue growth in its fiscal Q3 2022, achieving net revenues of $10.1 million. This increase was primarily driven by home care revenues of $9.0 million. Gross profit was 76.4% of net revenues, supported by higher Medicare pricing and operational efficiencies. Net income rose to $0.6 million, or $0.07 per diluted share, compared to the previous year's $0.2 million. The company announced a CFO transition and appointed Christopher Holland as Chief Commercial Officer to bolster growth initiatives.
Electromed, Inc. (AMEX: ELMD), a leader in airway clearance technologies, will participate in the Sidoti May Virtual Micro Cap Investor Conference on May 11-12, 2022. Kathleen Skarvan, President and CEO, and Mike MacCourt, CFO, will be available for one-on-one meetings during the event.
The group presentation by Electromed is scheduled for May 12 at 10:00 AM Eastern Time. Interested participants can register for the presentation via this link.
Electromed, Inc. (AMEX: ELMD) announced its financial results for the fiscal 2022 third quarter, ending March 31, 2022, will be released on May 10, 2022, after market close. A conference call to discuss these results will follow at 5:00 p.m. Eastern Time on the same day. Participants can join by dialing specific numbers provided in the release. For those unable to attend, a replay will be available via phone and online.
Electromed, Inc. has appointed Christopher Holland as Chief Commercial Officer to spearhead its strategic growth initiatives. With 30 years of experience in the Medical Technology sector, Holland previously held significant roles at Prosomnus Sleep Technologies and Nonin Medical, where he drove substantial revenue growth. CEO Kathleen Skarvan expressed confidence in Holland's ability to enhance marketing and sales strategies that align with the company’s revenue goals and shareholder value. This leadership shift aims to position Electromed prominently within the airway clearance market.
Electromed, Inc. (NYSE American: ELMD) reported record quarterly net revenues of $10.2 million for the fiscal second quarter ended December 31, 2021, up from $9.5 million year-over-year. Home care revenues drove this growth, totaling $9.4 million, despite a decline in gross profit margin to 76.9% due to rising raw material and shipping costs. Operating income decreased to $1.1 million, with net income at $0.8 million or $0.10 per diluted share. The company plans to continue strategic growth initiatives, including a focus on expanding its sales force and developing new product offerings.
Electromed, Inc. (AMEX: ELMD) announced that it will release its financial results for the fiscal 2022 second quarter, ending December 31, 2021, on February 8, 2022, after the market closes. A conference call to discuss these results will be held at 5:00 p.m. ET on the same day, accessible via phone for domestic and international callers. The event can also be streamed live on the Investor Relations section of their website.
Electromed, a leader in airway clearance technologies, announced its participation in the Sidoti December Virtual Micro Cap Investor Conference on December 8-9, 2021. Key executives, including President Kathleen Skarvan and CFO Mike MacCourt, will present on December 8 at 2:30 p.m. Eastern Time and will be available for one-on-one meetings. Electromed is known for its SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. The Company is based in New Prague, Minnesota, and has been operational since 1992.
Electromed, Inc. (NYSE American: ELMD) reported a record quarterly revenue of $10.0 million for Q1 FY 2022, reflecting a 25.0% increase year-over-year. Growth was driven by a 24.4% rise in home care revenue to $9.3 million and a 61.5% increase in institutional revenue. Gross profit margin improved to 77.0% despite rising costs. However, net income declined to $439,000 or $0.05 per diluted share. SG&A expenses rose to $6.8 million due to strategic investments. The company maintains $11.0 million in cash and continues to focus on product development and digital marketing strategies.
Electromed, Inc. (AMEX: ELMD) will release its fiscal 2022 Q1 financial results on November 9, 2021, after market close. A conference call will follow at 5:00 p.m. Eastern Time to discuss these results. Interested parties can join via phone or through a live webcast available on the company’s website. Electromed is known for its innovative airway clearance technologies, particularly the SmartVest Airway Clearance System, catering to patients with compromised pulmonary function.